AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
AbbVie Inc ABBV
$263.29
▼ -1.12%
($-2.99)
Index member:
S&P 500
⬇️ Below Yest. Low
Open
$265.45
Prev Close
$266.28
Day Range
$261.52 – $268.93
52W Range
$190.75 – $269.39
Market Cap
$465.26B
P/E (TTM)
74.57
Beta
0.20
Div Yield
4.47%
EPS (TTM)
$3.56
📋 Company Profile
| Industry | Biotechnology |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2013-01-02 |
| Shares Out. | 1,766,790,000 |
| Website | abbvie.com/ ↗ |
| Phone | 13023513367 |
| Employees | 57,000 |
| Revenue | $16.99B |
| Gross Profit | $12.70B |
| Net Income | $3.62B |
| Free Cash Flow | $18.21B |
| Total Assets | $135.12B |
| Total Liabilities | $141.00B |
| Equity | -$5.89B |
About AbbVie Inc
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
AbbVie Inc is a publicly traded company under the ticker symbol ABBV on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
39 analysts (2026-09-01)
📰 Latest News for ABBV
Defensive Dividends: 3 Companies Investors Can Rely On
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
Amazon, Walmart Surplus Auctioneer Climbs Toward A Breakout; Stock Up 45%
Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

